Last reviewed · How we verify
Autologous thyTreg — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Autologous thyTreg (Autologous thyTreg) — Rafael Correa-Rocha.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Autologous thyTreg TARGET | Autologous thyTreg | Rafael Correa-Rocha | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Autologous thyTreg CI watch — RSS
- Autologous thyTreg CI watch — Atom
- Autologous thyTreg CI watch — JSON
- Autologous thyTreg alone — RSS
Cite this brief
Drug Landscape (2026). Autologous thyTreg — Competitive Intelligence Brief. https://druglandscape.com/ci/autologous-thytreg. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing